JNJ
Another win for the oncology shelf
Johnson & Johnson dropped final overall survival data from the Phase 3 PAPILLON study, and the headline is simple: RYBREVANT (amivantamab-vmjw) plus carboplatin-pemetrexed outperformed chemo alone in first-line advanced NSCLC with EGFR exon 20 insertion mutations.
That matters because this is the kind of patient population where good news is scarce and survival numbers have historically looked rough. J&J is basically saying, “Hey, we didn’t just move the bar — we moved it into a different zip code.”
Why investors should care
This is the sort of clinical readout that can help keep a drug relevant, expand physician confidence, and support the long-term commercial story around RYBREVANT. In biotech-land, durability is everything; in big pharma-land, it’s even better when the durability comes with a marketable label and a nice little competitive moat.
The bigger picture
For J&J, this isn’t a moonshot Hail Mary. It’s more like slowly stacking bricks in the oncology fortress while the market watches to see which therapies turn into durable revenue engines.
Big picture: when a company with J&J’s scale gets a strong survival update in a hard-to-treat cancer setting, investors tend to perk up — because every extra bit of clinical proof is another chip in the pile toward future sales and staying power.